Immune-Related Adverse Events After Immune Checkpoint Inhibitors for Melanoma Among Older Adults.

ABSTRACT:

Importance

Immune checkpoint inhibitors (ICIs) have improved survival in patients with advanced melanoma but can be associated with a spectrum of immune-related adverse events (AEs), including both autoimmune-related AEs and other immune-related inflammatory AEs. These associations have primarily been evaluated in clinical trials that include highly selected patients, with older adults often underrepresented.

Objective

To evaluate the association between use of ICIs and immune-related AEs (autoimmune and other immune related) among older patients with cutaneous melanoma.

Design, setting, and participants

A population-based cohort study was conducted from January 1, 2011, to December 31, 2015. Data were analyzed from January 31 to May 31, 2021. With use of a linked dat

SUBMITTER: Schonfeld SJ 

PROVIDER: S-EPMC8941351 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature